Last reviewed · How we verify

HS628+MTX — Competitive Intelligence Brief

HS628+MTX (HS628+MTX) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: JAK inhibitor (presumed) in combination with antimetabolite. Area: Immunology / Rheumatology.

phase 3 JAK inhibitor (presumed) in combination with antimetabolite Immunology / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

HS628+MTX (HS628+MTX) — Zhejiang Hisun Pharmaceutical Co. Ltd.. HS628 is a small-molecule inhibitor combined with methotrexate (MTX) to target immune-mediated inflammatory conditions through dual pathway suppression.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
HS628+MTX TARGET HS628+MTX Zhejiang Hisun Pharmaceutical Co. Ltd. phase 3 JAK inhibitor (presumed) in combination with antimetabolite

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (JAK inhibitor (presumed) in combination with antimetabolite class)

  1. Zhejiang Hisun Pharmaceutical Co. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HS628+MTX — Competitive Intelligence Brief. https://druglandscape.com/ci/hs628-mtx. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: